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Background: Enterovirus 71 (EV71) is the etiologic agent of hand-foot-and-mouth disease (HFMD) in the Asia-Pacific
region, Many strategies have been applied to develop EV71 vaccines but no vaccines are currently available. Mucosal
immunization of the VP1, a major immunogenic capsid protein of EV71, may be an alternative way to prevent
EV71 infection.
Results: In this study, mucosal immunogenicity and protect function of recombinant VP1 protein (rVP1) in
formulation with chitosan were tested and assessed in female ICR mouse model. The results showed that the oral
immunization with rVP1 induced VP1-specific IgA antibodies in intestine, feces, vagina, and the respiratory tract
and serum-specific IgG and neutralization antibodies in vaccinated mice. Splenocytes from rVP1-immunized mice
induced high levels of Th1 (cytokine IFN-γ), Th2 (cytokine IL-4) and Th3 (cytokine TGF-β) type immune responses
after stimulation. Moreover, rVP1-immunized mother mice conferred protection (survival rate up to 30%) on neonatal
mice against a lethal challenge of 103 plaque-forming units (PFU) EV71.
Conclusions: These data indicated that oral immunization with rVP1 in formulation with chitosan was effective in
inducing broad-spectrum immune responses and might be a promising subunit vaccine candidate for preventing
EV71 infection.
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Enterovirus 71 (EV71), a positive-sense, single-stranded
RNA virus in the genus Enterovirus, family Picornaviridae,
is associated with a spectrum of diseases, including
HFMD, herpangina, encephalitis, aseptic meningitis,
cerebellar ataxia, poliomyelitis-like syndrome and even
some fatal diseases. There were several outbreaks of
EV71 infection over the last ten years in Taiwan and main-
land of China [1,2], and the infectious diseases caused by
EV71 infection have become a serious public health
threats in Asia, in particular to children.* Correspondence: 18910222351@163.com; lidx@chinacdc.cn
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unless otherwise stated.A wide range of strategies have been applied to develop
EV71 vaccines, including attenuated live vaccine [3,4],
inactivated vaccine [5,6], Virus-like particles (VLP) vaccine
[7], VP1 subunit [6] or DNA vaccine [6,8], et al. and their
efficacy has been studied in animals or even clinical trials.
However, most of the vaccines mentioned above were
delivered by injection which was general more costly,
difficult to administrated, and less acceptable to children.
Mucosal immunizations, including oral, intranasal, pul-
monary, rectal and vaginal routes of vaccine administration,
stimulate a stronger mucosal immune response that could
protect mucous membranes against microbial colonization
and invasion. Oral vaccination is a desirable alternative,
potentially allowing for safe, simple, rapid delivery and
takes advantage of the protection offered by intestinal
mucosa [9]. To potentiate mucosal immune responses
and protect antigens from the harsh environment ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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studies showed that chitosan, as a potential use non-toxic
delivery component, boosts both the humoral and cel-
lular immune responses of the mucosal surface after
co-administration with Helicobacter Pylori and influenza
vaccines [10,11] and causes little irritability or antigenicity.
The capsid of EV71 is comprised of 60 identical pro-
tomers, each of which contains a copy of four viral
structural proteins VP1-VP4. VP1 has been defined as a
major neutralizing antigen which effectively induces
immune protections against EV71 infection, has been
considered as potential subunit vaccine. Previous studies
identified major linear neutralizing epitopes and CD4+
T-cell epitopes within the VP1 protein [12,13], suggest-
ing it is a promising vaccine candidate. In this study,
the mucosal immunogenicity and protective function
of Escherichia coli (E. coli) expressed rVP1 protein in
formulation with chitosan were tested in female ICR mice
and the protective efficiency of the rVP1 immunogen was
evaluated in vitro and in vivo.
Materials and methods
Purification of EV71 Virions
Vero cells (ATCC CCL81) were cultured in Dulbecco’s
modified Eagle’s medium (DMEM; Gibco) with 10%
heat-inactivated fetal bovine serum (FBS), penicillin and
streptomycin (PS; 100U/ml) at 37°C with 5% CO2. EV71
strain (HN08) (Genebank No. HM038013) used in this
study was isolated in Henan province and was propagated
in Vero cells cultured in DMEM containing 2% FBS and
PS (100 U/ml). When 90% of cells exhibited cytopathic
effect (CPE), supernatants were harvested and inactivated
with β-propiolactone (1:2000). Crude supernatants were
centrifuged at 12,000 × g for 30 min to remove cellular
debris and filtered through a 0.22-μm pore-size membrane
(Millipore, MA, USA). Then the supernatants were
concentrated by Vivaflow membrane (Sartorius stedim,
Germany) according to the manufacture instruction. The
concentration product was purified using gel filtration
chromatography by sepharose 4FF and then ion exchange
exclusion chromatography by DEAE-sepharose Fast Flow
column (GE Healthcare, England). The purity of the EV71
virions was detected by high performance liquid chro-
matography (HPLC) (SHIMADZU, Japan) and quantified
with the BCA protein assay kit (ThermoFisher, USA).
EV71 particles were stored at −80°C.
Construction of EV71 VP1 protein expression plasmid
QIAamp viral RNA mini Kit (Qiagen, Germantown, MD,
USA) was used to extract EV71 RNA from infected Vero
cell supernatants. Transcriptor High Fidelity cDNA Syn-
thesis Kit (Roche, Indianapolis, IN, USA) was used for
cDNA synthesis. The total 891 basepairs fragment of
VP1 gene (Genebank No.HM038013) was amplified bypolymerase chain reaction (PCR) using forward primer
VP1(1–19)-F:CGCCATATGGGAGATAGGGTGGCAGA
TG and reverse primer VP1(874–891)-R:CCGCTCGA-
GAAGAGTGGTGATCGCTGT, the PCR product was
digested with NdeI and XhoI and then cloned into
pET30a vector (Novagen, Billerica, MA, USA) and named
pET30a-VP1, the encoded fusion protein had a His-tag at
the C-terminus.
Purification and identification of recombninat VP1 protein
and EV71 virions
BL21 (DE3) was transformed with pET30a-VP1 by the
Ca2+ phosphate method [14]. Single clone was selected
and inoculated into Luria Broth (LB) culture medium
containing kanamycin (50 mg/ml). The culture medium
was rotated at 37°C until the OD600 reached 0.6–0.7,
culture medium was transplanted (1:1000 ratio) into
1.5-L Erlenmeyer flasks. Induction and purification of
protein was according to the pET System Manual
(11th edition, Novagen) using the Ni2+ affinity method.
Further, potential endotoxin Lipopolysaccharide (LPS)
in purified rVP1 protien solution was removed using
ion exchange exclusion chromatography by Q Sepharose
Fast Flow column (GE Healthcare, England), then the
LPS levels were determined using the Limulus amebocyte
lysate assay kit (ACC, USA ) according to manufacture
instruction. Purified EV71 virions obtained from Beijing
Institute of Biological Products Company Limited was
analyzed by SDS-PAGE with 4-20% Mini-Protein TGX™
Gel (Bio-Red Cat No 4561093, USA) followed by staining
with Coomassie brilliant blue. For western blot, proteins
were transferred to polyvinylidene fluoride membranes
(Bio-Rad, Hercules, CA, USA). Membranes were blocked
for 1 h in 5% skim milk at room temperature followed by
incubation with purified human recombinant monoclonal
antibody to EV71 VP1, which was derived from a phage
display liberary and converted to IgG form in bacuovirus/
SF9 cell system [15]. Goat anti-human IgG conjugated
to alkaline phosphatase was used as the second anti-
body. Signals were visualized with NBT/BCIP substrate
(Roche, Germany).
Preparation of immunogen EV71 rVP1-Chi and mice
immunization
Immunogen rVP1-Chi was obtained by adding purified
rVP1 40 μg or 160 μg to 1 ml 0.02% chitosan-phosphate
buffer solution (PBS) (pH5.7) (Sigma, St. Louis, MO, USA).
And high speed vortexing was used until the solution
was homogenated. EV71 virions formulation was prepared
as the rVP1. Female ICR mice (8 weeks old) were divided
randomly into eight groups: (1) 40 μg rVP1 antigen
(rVP1-40); (2) 160 μg rVP1 antigen (rVP1-160); (3)
40 μg rVP1 antigen with chitosan adjuvant (rVP1-40-
Chi); (4) 160 μg rVP1 antigen with chitosan adjuvant
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(Virion-40); (6) 40 μg purified EV71 virions antigen
with chitosan adjuvant (Virion-40-Chi); (7) PBS (PBS);
(8) PBS mixed with chitosan solution (PBS-Chi). Before
oral immunization, mice were starved overnight and fed
with sodium bicarbonate buffer to neutralize gastric acid.
Eight mice per-group were immunized intragastrically on
day 0, 7, 14 and 28. Blood samples were collected and
centrifuged at 5000 × g, 4°C. Serum was inactivated at
56°C for 30 min and stored at −80°C until used for
neutralization assays and measurement of serum IgG.
Vaginal, respiratory tract, and small intestine secretions
were collected by cold PBS washes (containing 0.5%
saponin (w/v); 50 mM EDTA; and 0.1 mg/ml trypsin
inhibitor) [16]. Fresh fecal pellets were collected on day
42, and immediately frozen at −80°C. Before analysis,
0.2 g feces was dissolved in 400 μl of cold PBS (con-
taining 0.01% sodium azide and 1 mM EDTA), and the
suspensions stirred and centrifuged at 9000 × g for 10 min.
IgA in the supernatants was assayed by enzyme linked
immunosorbent assay (ELISA) [17].
Measurement of specific antibodies
VP1-specific IgG antibodies were measured by indirect
ELISA by coating 96-well plates with EV71 virions
(100 ng/well), overnight at 4°C. After blocking with
5% skim milk to avoid nonspecific binding, Serum
diluted in 5% skim milk was added to each well and
incubated for 1 h at 37°C. After washing with PBS
contain 0.05% tween-20 (PBST, V/V), horse radish
peroxidase (HRP) -conjugated goat anti-mouse IgG or
anti-mouse IgA (Sigma, St. Louis, MO, USA) was added
and incubated for 1 h at 37°C. 3,3’,3,5’-tetramethylbenzi-
dine (TMB) was added as substrate, and absorbance was
measured at 450 nm. The positive cut-off value was an
optical density (OD) value 2.1-fold above normal negative
control sample.
Serum neutralization assay
The mice serum neutralizing antibodies against EV71 were
analyzed using the cytopathic effect (CPE)-determination
assay based on Vero cells. Briefly, mice sera from all groups
were heat-inactivated at 56°C for 30 min, then were
two-fold serially diluted from 1:4 to 1:256 in DMEM
(2% FBS, 1% PS) and mixed with the same volume of
200 tissue culture infective dose 50 (TCID50) EV71
virus. After 2 h incubation at 37°C, 100 μl of virus-serum
mixture was added to each well of the 96-well plates and
followed by 100 μl of 2 × 105/ml Vero cells. Every dilution
of each serum sample was performed in quadruplicate.
The plates were then incubated in a CO2 incubator at 37°C
for 7 days. The neutralizing antibody titer was expressed
as the maximum serum dilution at which CPE was not
observed in all four wells. The serum dilution titer atstart point of 1:4 was considered as the cut off value
for sero-conversion determination.
Splenocyte proliferation assay and cytokine production
Splenocytes were isolated from ICR mice from each vac-
cine group, which were sacrificed 6 weeks after primary
inoculation, and cultured in 96-well plates (1 × 106 cells
per well) in 200 μl RPMI medium 1640 (10% FBS, 1%
PS). 1 μg purified rVP1 protein was used as antigenic
stimulant per well and concanavalin A (Con A) was served
as positive control. Furthermore, to eliminate the cell acti-
vation due to the LPS contamination, splenocytes were
also stimulated by nucleocapsid protein (NP) of Hantaan
virus, which was expressed and purified the same way as
rVP1. Plates were incubated at 37°C for 72 h. Culture
supernatants from proliferating splenocytes were collected
and the level of IFN-γ, IL-4, IL-5 and TGF-β were detected
using mouse ELISA kits (R&D, Minneapolis, MN, USA).
The concentration values of cytokines stimulated by rVP1
were all subtracted those stimulated by hantaan virus NP
and were expressed as mean ± SD.
Lethal EV71 challenge suckling mice
Because EV71 infection caused no apparent clinical symp-
toms in adult mice, viral challenge was performed using
newborn mice. The 8-week-old female ICR mice received
vaccination of rVP1-40, rVP1-40-Chi, rVP1-160, rVP1-
160-Chi, Virion-40, Virion-40-Chi, PBS, and PBS-Chi as
described above at day 0, 7, 14 and were allowed to mate.
The mice received a booster 2 weeks later and neonatal
mice were born at week 5 to week 6, then challenged
intracerebrally with 10 μl (105 PFU/ml) EV71 48–72 h
after birth. Meanwhile, a challenge-free group was also
included in this experiment in order to provide a basic
survival background. The clinical symptoms and body
weight changes of challenged suckling mice were recorded
daily and the scores were graded as: health (0), inactivity
and/or wasting (1), limb-shake weakness (2), hind limb
paralysis (3), moribund and death (4).
Statistical analysis
Results are expressed as mean ± SD. Significant differences
between groups were analyzed using SPSS 11.5 (IBM,
Chicago, IL, USA). P < 0.05 was considered statically sig-
nificant. Significant differences between two means are
presented as P < 0.05 (*) and P < 0.01 (**).
Results
Identification of EV71 virions and rVP1 protein
Purified EV71 virions and recombinant VP1 protein were
characterized by SDS-PAGE and western blot analysis
using anti-VP1 antibody. As shown in Figure 1, SDS-
PAGE of EV71 virions demonstrated the presence of
VP0, VP1, VP2 and VP3. The molecular weight of EV71
Figure 1 Identification of purified EV71 virions and recombinant VP1. Purified EV71 virions and rVP1 were identified by SDS-PAGE and
Western blot analysis. (A) SDS-PAGE (up) and Western blot analysis (below) of purified EV71 virions. SDS-PAGE demonstrated the presence of
VP0, VP1, VP2 and VP3, which was indicated by arrow bars and Western blot detected by anti-VP1 antibody showed specific reaction band of
VP1 at molecular weight of 36 kDa. (B) SDS-PAGE (up) and Western blot analysis (below) of purified rVP1. Lane1, Marker. Lane2, BL21(DE3).
Lane3, rVP1 expressed in BL21(DE3). Lane4, purified rVP1.
Figure 2 Titer profiles of total IgG and neutralizing antibody.
(A) Titers of total anti-EV71 IgG. Data were expressed as mean ± SD.
(*P < 0.05, ** P < 0.01). (B) Neutralization titers. Groups of female ICR
mice (n = 8) were Immunized orally on days 0,7,14 and 28 with
different formulation of vaccine, the dot line indicate the initial
dilution of mice serum.
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authentic virions. Western blot analysis detected by specific
antibody further confirmed the identity of rVP1, showing
that both virions and rVP1 presented similar reaction bands
at molecular weight of 36 kDa. The purity was above 95%
for EV71 virions and rVP1 as assessed by HPLC. And the
concentration of rVP1 protein was finally adjusted to 2 mg/ml
with BCA kit (Pierces, USA), in which the LPS level was de-
tected below 1500 EU/mg with the kit mentioned above.
Recombinant VP1 elicits specific IgG and neutralization
antibodies
To determine whether the recombinant VP1 protein was
capable of eliciting anti-EV71 antibodies, serum samples
of eight groups of female ICR mice were collected six
weeks after primary immunization for antibody assays.
As is shown in Figure 2A, in comparison to PBS control
group, specific IgG antibodies could be detected in all
vaccine-immunized groups after three times of boosts
when using EV71 virions as coating antigen of ELISA.
Groups of 160 μg rVP1 or rVP1-Chi induced higher
levels of specific IgG antibody titers (1:1600 or 1:3200)
than those received 40 μg rVP1 or rVP1-Chi (1:200 or
1:800) (P < 0.05) (Figure 2A) and the chitosan could
significantly enhance the titer of IgG antibodies (P < 0.05)
(Figure 2A) when giving the same dose of antigen. No
significant differences between rVP1 and EV71 virions
groups were observed.
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virus in vitro was examined by neutralization assay based
on Vero cell. Results showed that mice immunized with
rVP1-160 or rVP1-160-Chi developed neutralizing anti-
body titers that could effectively against homologous
EV71 strain at dilutions of 1:4 or 1:8. The sera conver-
sion rate for neutralization antibodies was 37.5% (3/8)
in rVP1-160 group and 87.5% (7/8 in rVP1-160-Chi group,
respectively (Figure 2B). However, as the specific IgG titers
were lower than rVP1-160 μg group, the neutralizing anti-
bodies were not detected (lower than 1:4) in the groups
of rVP1-40, rVP1-40-Chi, virion-40 and virion-40-Chi
indicated that higher dose of rVP1 mucosal immunization
may be required for efficiency neutralizing antibody pro-
duction and specific T cell responses.
Recombinant VP1 induces specific mucosal IgA antibodies
To test whether EV71 rVP1 can elicit mucosal immune
responses, samples in Vaginal, respiratory tract, small
intestine secretions and feces were collected on day 42Figure 3 Detection of EV71 specific mucosal IgA antibody. Secretions o
on day 42 and immediately frozen at −80°C. Titers of specific IgA antibody in:
(C) Respiratory tract (diluted at 1:2); (D) Vaginal secretions (diluted at 1:2)
OD.450 value ± SD. (* P < 0.05, ** P < 0.01).after the first inoculation and mucosal IgA antibody titers
were measured by ELISA. Results showed that mice
immunized with either EV71 rVP1 or virions displayed
apparent mucosal responses as compared with PBS
negative control groups (Figure 3). Furthermore, the mice
immunized with 160 μg rVP1 significantly (P < 0.05) in-
duced higher mucosal IgA levels than the mice immunized
with 40 μg rVP1. Again the mucosal responses elicited by
mice immunized with chitosan associated rVP1 or virions
were also significantly higher (P < 0.05) than those of mice
immunized with non-associated antigens when giving the
same dose. No statistical difference was observed between
groups of recombinant VP1 protein and virions.
Cytokine production profiles
Profiles of cytokine production by splenocytes were stud-
ied as indicators of the polarization of Th1/Th2 immune
response. The IFN-γ, IL-4, IL-5 and TGF-β cytokines in the
supernatants of splenocytes after stimulation with rVP1
were investigated by ELISA (Figure 4). Groups of micef vaginal, intestinal, respiratory tract and fresh fecal pellets were collected
(A) Intestine (diluted at 1:10); (B) Stool homogenates (diluted at 1:4);
were detected by indirect ELISA. Data were expressed as mean
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levels of IFN-γ compared with mice immunized with
PBS (P < 0.05) (Figure 4A), confirming the induction of
Th1 cellular immune responses by oral inoculation.
Splenocytes of mice immunized with high-dose antigen
produced significantly higher levels of IFN-γ than mice
vaccinated with low-dose antigen (P < 0.05) and the chi-
tosan enhanced induction of the Th1 cellular immune
response when high-dose of rVP1 administrated (P < 0.05).
No significant differences were observed between groups
immunized with 40 μg rVP1 protein and virions. As for
cytokine IL-4 detection (Figure 4B), which is the indicator
of Th2 immune responses, spleen cells of mice immunized
with recombinant VP1 protein or virions produced higher
level of IL-4 than PBS control groups (P < 0.05). Spleno-
cytes derived from the rVP1-160-Chi group produced
the highest level of IL-4. These results demonstrated
that rVP1 antigen could induce a mixed Th1 and Th2
immune response in the ICR mouse model. Splenocytes of
mice immunized with vaccine groups including rVP1-40,
rVP1-40-Chi, rVP1-160, rVP1-160-Chi, virion-40 and
virion-40-Chi produced higher levels of TGF-β than PBS
group, and the chitosan could enhance induction of TGF-Figure 4 Cytokine production profiles. Splenocytes from groups of imm
Concentrations of (A) IFN-γ. (B) IL-4. (C) IL-5. (D) TGF-β in the culture supe
cytokines were expressed as mean ± SD. (* P < 0.05, ** P < 0.01).β when giving 160 μg of rVP1 (P < 0.05) (Figure 4D). The
production of IL-5 was low overall and no significant
difference between groups was detected (Figure 4C).
Recombinant VP1 protects suckling ICR mice against
lethal virus challenge
Protection against lethal EV71 infection by the passively
transferred maternal antibody from immunized dams was
evaluated in newborn ICR mice. 2 days after challenge,
un-protected neonatal mice started to show clinical symp-
toms, such as wasting, hind-limb paralysis and eventually
deaths were occurred within 2 weeks (Figure 5A,B,C,E,F).
At virus challenge dose of 103 PFU, the protection in
newborns was markedly different according to the vaccine
preparation received by their mothers (Figure 5D). The
suckling mice born to dams that received rVP1-160-Chi,
in which group the neutralizing antibody titers were
about 1:8, showed a protective efficacy of 30.0% (9/30).
Protection efficacy against lethal infection was 13.8%
(4/29) for rVP1-40-Chi, 20% (6/30) for rVP1-160 (neu-
tralizing antibody titers were 1:4) and 10% (3/30) for
the group that received Virion-40-Chi. Groups that re-
ceived rVP1-40 (0/24), Virion-40 (0/30), PBS (0/30) orunized mice were stimulated with recombinant VP1 protein for 72 h.
rnatants were determined by ELISA. The concentration values of
Figure 5 Lethal EV71 challenge of newborns from immunized female mice. Two-day-old pups from immunized female mice were intracerebrally
inoculated with EV71. (A) Unchallenged suckling mouse (B) representative mouse in the PBS group with limb paralysis and wasting (arrows) at 3 days
post-infection with EV71 virus; (C) protected mouse challenged with EV71 virus; (D) survival rate after viral challenge of suckling mice from mothers
immunized with different oral vaccines; (E) mean clinical scores for clinical symptoms of pups from female mice immunized with different vaccines;
(F) weight changes in suckling ICR mice after EV71 challenge. Body weights were recorded for all surviving mice daily until 14 days post-infection.
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mice and all challenged mice died within 14 days (Fig-
ure 5D). Meanwhile, all newborn ICR mice in challenge
free group survived.Discussion
The human pathogen of EV71 causes the infectious disease
HFMD mostly in children. The virus initiates children
infection via the mucosal surfaces and therefore the
mucosal immunization could be a promising way to
achieve protection against the virus infection in human.
In this study, the efficacy and protective functions of
oral immunization with chitosan and recombinant EV71
VP1 formulations were analyzed and evaluated in ICR
mouse model with lethal challenge of EV71, and the
results presented that chitosan help EV71 rVP1 induced
better VP1-specific IgA antibodies in intestine, feces,
vagina, and respiratory tract, and systemic specific IgG and
neutralization antibodies in humoral immune responses as
well as the Th1 and Th2 cellular immune responses.
The mucosal surfaces of the gastrointestinal, genitouri-
nary, and respiratory tracts are the primary entry sites
of most pathogens. The induction of effective mucosalimmunity could greatly reduce the infection rate and
morbidity. Thus, mucosal immunization, especially by
the oral route, has recently attracted much interest. IgA
is thought to protect the host against pathogens that
infect mucosal surfaces and those that cause systemic
disease after entry via a mucosal surface [18]. In our
study, rVP1 oral vaccine induced specific IgA antibody
immune response on the mucosal surface. IgA antibody
was detected in feces and washes of small intestine, and
also detected in the mucosal secretion of vagina and
respiratory tract. The reason might be the different
mucosal surfaces are interconnected via circulating lym-
phocytes, recognized as the common mucosal immune
system [19], which lead immunization at one mucosal
inductive site to an immune response at a remote
mucosal effective site. Except the mucosal IgA antibody
production, we also find the cytokine TGF-β related to
IgA production was significantly elevated from rVP1
160 μg with chitosan, suggest that the involvement of
TGF-β in the mucosal IgA antibody response in the
mice immunized with rVP1. TGF-β was produced mainly
by the Th3 type lymphocytes, the production of cytokine
TGF-β indicated the Th3 type immune responses involved
in the rVP1 mucosal immune responses. However, as
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secretion was observed in our study.
Oral immunization is complicated by antigen degrad-
ation in the gastrointestinal tract and low uptake into M
cells in Peyer's Patches. Induction of immune responses
following oral immunization is usually dependent on
the co-administration of appropriate adjuvant that can
initiate and support the transition from innate to adaptive
immunity. In this study, we chose chitosan as a mimic
adjuvant or a component in vaccine delivery system to
enhance the immunogenicity of the rVP1, our results
showed that chitosan based delivery and adjuvant formu-
lations were effective in production of specific humoral
and cellular immune responses and protection of ICR
mice form EV71 challenge. Chitosan is a naturally occur-
ring polysaccharide material that is biodegradable and
non-toxic. Due to the function of penetration and uptake
enhancement and antigen protection, chitosan has been
clearly demonstrated as a promising candidate for mucosal
vaccine delivery system in mice [21,22], it has also been
reported to have immune stimulating activities such as
increasing the accumulation and activation of macrophages,
promoting resistance to infections by enhancing innate
and cytotoxic T lyphocyte (CTL) immune responses [23].
However, the working mechanisms of chitosan in vaccine
delivery system still need to be further understood.
In this study, we also find that both rVP1-160 and
rVP1-160-Chi groups developed high titers of specific
antibodies and effective neutralizing antibodies, but the
neutralizing antibodies were not detectable for groups
of rVP1-40, rVP1-40-Chi, virion-40 and virion-40-Chi.
However, both rVP1 doses of 160 μg and 40 μg with
chitosan showed certain level of protection rate in
EV71 challenged ICR mice although the protection
rates were not satisfied. The in vivo functions of the
neutralizing antibodies for rVP1-40-Chi and virion-40-
Chi groups may not be sensitively measured by the
micro-neutralizing assay in vitro. On another hand, the
protective function in vivo may be not only offered by
the neutralizing antibodies and the cellular immune
responses. The cell-mediated immune responses were
also detected after oral immunization. Administration
of rVP1 with chitosan induced increases in the levels
of the secreted Th1 cytokine IFN-γ and Th2 cytokine
IL-4 in immunized mice indicating that the EV71 rVP1
oral vaccine might have triggered Th1 and Th2 immune
responses, which are involved in cellular-mediated immun-
ity. Innate immune responses might also be important
in protection of newborn mice against EV71 challenge.
This might explain of the differences in the in vitro and
in vivo experimental results. Furthermore, virions usually
induced better humoral and cellular immune response in
intramuscular injection type of vaccine. But in this study,
the virions at dose 40 μg could not induce better antibodytiters and the T cell responses as the rVP1-40 group. The
reason might be the digestion effect of gastric acid and
protease, the antigen achieved the effective target sites in
small intestine was limited. The higher dose virus particles
may stimulate better immune response.
Conclusions
In conclusion, oral delivery of rVP1 in formulation with
chitosan induced systemic humoral and multi-mucosal
immune responses, as neutralization antibodies blocked
EV71 from infecting host cells in vitro and maternally
transferred antibodies or cellular immunity protected
neonatal mice against EV71 challenge in vivo. Our results
indicate that oral immunization with rVP1 in formulation
with chitosan is effective in inducing broad-spectrum
immune responses and may be a promising subunit
vaccine candidate for the prevention of EV71 infection,
a non-invasive oral vaccination strategy may be an
attractive alternative for developing countries, in particular
acceptable to children and easier for vaccination in devel-
oping countries.
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